Research Article| Volume 30, ISSUE 10, P1932-1933, October 2008

Download started.


Dear Dr. Walson

      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Niemi M
        • Backman JT
        • Fromm MF
        • et al.
        Pharmacokinetic interactions with rifampicin: Clinical relevance.
        Clin Pharmacokinet. 2003; 42: 819-850
        • Fromm MF
        • Kauffmann HM
        • Fritz P
        • et al.
        The effect of rifampin treatment on intestinal expression of human MRP transporters.
        Am J Pathol. 2000; 157: 1575-1580
        • Kim KA
        • Park PW
        • Liu KH
        • et al.
        Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone.
        J Clin Pharmacol. 2008; 48: 66-72
        • Kyrklund C
        • Backman JT
        • Kivisto KT
        • et al.
        Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations.
        Clin Pharmacol Ther. 2000; : 592-597
        • Backman JT
        • Luurila H
        • Neuvonen M
        • Neuvonen PJ
        Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
        Clin Pharmacol Ther. 2005; 78: 154-167
        • Scripture CD
        • Pieper JA
        Clinical pharmacokinetics of fluvastatin.
        Clin Pharmacokinet. 2001; 40: 263-281
        • Kyrklund C
        • Backman JT
        • Neuvonen M
        • Neuvonen PJ
        Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects.
        Br J Clin Pharmacol. 2004; 57: 181-187
        • Evers R
        • Chu XY
        Role of the murine organic anion-transporting polypeptide 1b2 (Oatp1b2) in drug disposition and hepatotoxicity.
        Mol Pharmacol. 2008; 74: 309-311
        • Sakaeda T
        • Fujino H
        • Komoto C
        • et al.
        Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.
        Pharm Res. 2006; 23: 506-512
        • Zhang W
        • Deng S
        • Chen XP
        • et al.
        Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: A randomized, single-blind, placebo-controlled, crossover study.
        Clin Ther. 2008; 30: 1283-1289
        • Treiber A
        • Schneiter R
        • Häusler S
        • Stieger B
        Bosentan is a substrate of human OATP1B1 and OATP1B3: Inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.
        Drug Metab Dispos. 2007; 35: 1400-1407
        • Lau YY
        • Huang Y
        • Frassetto L
        • Benet LZ
        Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers.
        Clin Pharmacol Ther. 2007; 81: 194-204
        • Oswald S
        • Giessmann T
        • Luetjohann D
        Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins.
        Clin Pharmacol Ther. 2006; 80: 477-485
        • Martin PD
        • Warwick MJ
        • Dane AL
        Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers.
        Clin Ther. 2003; 25: 2822-2835